Opioid Use DisorderSymptoms, Doctors, Treatments, Advances & More
Opioid Use Disorder Overview
Learn About Opioid Use Disorder
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Brigham And Women's Hospital, Department Of Psychiatry
Dr Suzuki is the Director of the Division of Addiction Psychiatry in the Department of Psychiatry, Brigham and Women’s Hospital (BWH), and an Assistant Professor of Psychiatry at Harvard Medical School (HMS). He has been a consultation-liaison psychiatrist in the Division of Medical Psychiatry at BWH, and serves as the Program Director for the BWH Addiction Medicine Fellowship Program. He has been very active in both medical student and resident education throughout his career. He is a member of Motivational Interviewing Network of Trainers and is the course director for the HMS CME course on motivational interviewing. His research has received funding from National Institute on Drug Abuse (NIDA), CDC, SAMHSA, BWH, and HMS. In 2018 he was awarded a NIDA K23 Career Development Award to receive mentored training in conducting clinical trials, and to study the impact of recovery coaches on hospitalized patients with opioid use disorder. He is a sought-out speaker both locally and nationally, and currently serves on a variety of committees, workgroups, and taskforces for Mass General Brigham, HMS, American Academy of Addiction Psychiatry, Academy of Consultation Liaison Psychiatry, and the State of Massachusetts. He has published 80 manuscripts and book chapters as first or co-author. Dr. Suzuki is rated as an Elite provider by MediFind in the treatment of Opioid Use Disorder. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Opioid Use Disorder and Delirium. Dr. Suzuki is board certified in Psychiatry, Addiction Medicine, and Addiction Psychiatry.
CUIMC/Herbert Pardes Building Of The New York State Psychiatric Institute
Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University. For over twenty years, she served as the Director of the Addiction Psychiatry Fellowship Program at New York-Presbyterian Hospital and for the past sixteen years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship which has been continuously funded since 1994. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. Subsequently, she graduated from a 2-year combined clinical and research fellowship at the University of Maryland and the Addiction Research Center, the intramural branch of the National Institute on Drug Abuse (NIDA). Currently, she serves as the Medical Director of the Providers’ Clinical Support System (PCSS), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant (the Opioid Response Network) to address the national opioid epidemic.Dr. Levin, working with other senior faculty, inaugurated the university-wide Center for Healing of Opioid and Other Substance Use Disorders: Enhancing Intervention Development and Implementation (CHOSEN) in 2020 and serves as one of the senior Directors. Moreover, she is the principal investigator of several federal grants, including a K24 Mid-Career Investigator Award as well as a Co-Investigator on numerous other grants.Her current research interests include pharmacologic and psychotherapeutic treatment interventions for opioid, cocaine and marijuana use disorders, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses. Dr. Levin has over two-hundred and fifty articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment, and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders. She has served on several advisory panels and ad-hoc federal grant review groups and was a member of the NIDA – Initial Review Group: Training and Career Development Subcommittee for eight years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is currently on the Board of Directors for the American Academy of Addiction Psychiatry (AAAP), the College on Drug Dependence (CPDD), and the American Society of ADHD and Related Disorders (APSARD). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry, and past Chair of the APA Council on Addiction Psychiatry. Dr. Levin is rated as an Elite provider by MediFind in the treatment of Opioid Use Disorder. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Opioid Use Disorder, Attention Deficit Hyperactivity Disorder (ADHD), and Post-Traumatic Stress Disorder (PTSD). Dr. Levin is board certified in Psychiatry and Addiction Psychiatry.
Kentucky Medical Services Foundation, Inc
Michelle Lofwall is a Psychiatrist and an Addiction Medicine provider practicing medicine in Lexington, Kentucky. Dr. Lofwall is rated as an Elite provider by MediFind in the treatment of Opioid Use Disorder. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Opioid Use Disorder.
Summary: The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Summary: The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximate...

